Cargando…

Lysosomal storage disorders: Molecular basis and laboratory testing

Lysosomal storage disorders (LSDs) are a large group of more than 50 different inherited metabolic diseases which, in the great majority of cases, result from the defective function of specific lysosomal enzymes and, in cases, of non-enzymatic lysosomal proteins or non-lysosomal proteins involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Filocamo, Mirella, Morrone, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500170/
https://www.ncbi.nlm.nih.gov/pubmed/21504867
http://dx.doi.org/10.1186/1479-7364-5-3-156
_version_ 1782250067182223360
author Filocamo, Mirella
Morrone, Amelia
author_facet Filocamo, Mirella
Morrone, Amelia
author_sort Filocamo, Mirella
collection PubMed
description Lysosomal storage disorders (LSDs) are a large group of more than 50 different inherited metabolic diseases which, in the great majority of cases, result from the defective function of specific lysosomal enzymes and, in cases, of non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal biogenesis. The progressive lysosomal accumulation of undegraded metabolites results in generalised cell and tissue dysfunction, and, therefore, multi-systemic pathology. Storage may begin during early embryonic development, and the clinical presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease. The diagnosis of most LSDs--after accurate clinical/paraclinical evaluation, including the analysis of some urinary metabolites--is based mainly on the detection of a specific enzymatic deficiency. In these cases, molecular genetic testing (MGT) can refine the enzymatic diagnosis. Once the genotype of an individual LSD patient has been ascertained, genetic counselling should include prediction of the possible phenotype and the identification of carriers in the family at risk. MGT is essential for the identification of genetic disorders resulting from non-enzymatic lysosomal protein defects and is complementary to biochemical genetic testing (BGT) in complex situations, such as in cases of enzymatic pseudodeficiencies. Prenatal diagnosis is performed on the most appropriate samples, which include fresh or cultured chorionic villus sampling or cultured amniotic fluid. The choice of the test--enzymatic and/or molecular--is based on the characteristics of the defect to be investigated. For prenatal MGT, the genotype of the family index case must be known. The availability of both tests, enzymatic and molecular, enormously increases the reliability of the entire prenatal diagnostic procedure. To conclude, BGT and MGT are mostly complementary for post- and prenatal diagnosis of LSDs. Whenever genotype/phenotype correlations are available, they can be helpful in predicting prognosis and in making decisions about therapy.
format Online
Article
Text
id pubmed-3500170
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35001702012-11-17 Lysosomal storage disorders: Molecular basis and laboratory testing Filocamo, Mirella Morrone, Amelia Hum Genomics Review Lysosomal storage disorders (LSDs) are a large group of more than 50 different inherited metabolic diseases which, in the great majority of cases, result from the defective function of specific lysosomal enzymes and, in cases, of non-enzymatic lysosomal proteins or non-lysosomal proteins involved in lysosomal biogenesis. The progressive lysosomal accumulation of undegraded metabolites results in generalised cell and tissue dysfunction, and, therefore, multi-systemic pathology. Storage may begin during early embryonic development, and the clinical presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease. The diagnosis of most LSDs--after accurate clinical/paraclinical evaluation, including the analysis of some urinary metabolites--is based mainly on the detection of a specific enzymatic deficiency. In these cases, molecular genetic testing (MGT) can refine the enzymatic diagnosis. Once the genotype of an individual LSD patient has been ascertained, genetic counselling should include prediction of the possible phenotype and the identification of carriers in the family at risk. MGT is essential for the identification of genetic disorders resulting from non-enzymatic lysosomal protein defects and is complementary to biochemical genetic testing (BGT) in complex situations, such as in cases of enzymatic pseudodeficiencies. Prenatal diagnosis is performed on the most appropriate samples, which include fresh or cultured chorionic villus sampling or cultured amniotic fluid. The choice of the test--enzymatic and/or molecular--is based on the characteristics of the defect to be investigated. For prenatal MGT, the genotype of the family index case must be known. The availability of both tests, enzymatic and molecular, enormously increases the reliability of the entire prenatal diagnostic procedure. To conclude, BGT and MGT are mostly complementary for post- and prenatal diagnosis of LSDs. Whenever genotype/phenotype correlations are available, they can be helpful in predicting prognosis and in making decisions about therapy. BioMed Central 2011-03-01 /pmc/articles/PMC3500170/ /pubmed/21504867 http://dx.doi.org/10.1186/1479-7364-5-3-156 Text en Copyright ©2011 Henry Stewart Publications
spellingShingle Review
Filocamo, Mirella
Morrone, Amelia
Lysosomal storage disorders: Molecular basis and laboratory testing
title Lysosomal storage disorders: Molecular basis and laboratory testing
title_full Lysosomal storage disorders: Molecular basis and laboratory testing
title_fullStr Lysosomal storage disorders: Molecular basis and laboratory testing
title_full_unstemmed Lysosomal storage disorders: Molecular basis and laboratory testing
title_short Lysosomal storage disorders: Molecular basis and laboratory testing
title_sort lysosomal storage disorders: molecular basis and laboratory testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500170/
https://www.ncbi.nlm.nih.gov/pubmed/21504867
http://dx.doi.org/10.1186/1479-7364-5-3-156
work_keys_str_mv AT filocamomirella lysosomalstoragedisordersmolecularbasisandlaboratorytesting
AT morroneamelia lysosomalstoragedisordersmolecularbasisandlaboratorytesting